NCT00355238 2023-12-01
A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
Bristol-Myers Squibb
Phase 2 Completed
Bristol-Myers Squibb
University of Rochester
University of Rochester
Dana-Farber Cancer Institute
Toronto Rehabilitation Institute